News
SAGE
12.95
+0.39%
0.05
SAGE Therapeutics Inc <SAGE.OQ> expected to post a loss of $1.65 a share - Earnings Preview
SAGE Therapeutics Inc expected to post a loss of $1.65 a share. The company is expected to report a 71.8% increase in quarterly revenue to $5.658 million. The mean estimate from 17 analysts is for the company to report quarterly revenue of $3.29 million.
Reuters · 4h ago
Weekly Report: what happened at SAGE last week (0415-0419)?
Weekly Report · 1d ago
Analysts Conflicted on These Healthcare Names: SAGE Therapeutics (SAGE), Accolade (ACCD) and Intuitive Surgical (ISRG)
TipRanks · 1d ago
What's in Store for Biogen (BIIB) This Earnings Season?
NASDAQ · 4d ago
SAGE Therapeutics Adjusts Inducement Equity Plan and Sets End Date
TipRanks · 4d ago
Netflix, ON Semiconductor And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Shares of Netflix, Inc. Fell 6% in today's pre-market trading following first-quarter results. Netflix added 9.33 million paid net new subscribers in the first quarter. Critical Metals Corp. Shares fell 12.3% after surging 12% on Thursday. U.S. Stock futures were lower this morning.
Benzinga · 4d ago
FYBR, BCRX and SABR are among after hour movers
Seeking Alpha · 4d ago
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
NASDAQ · 5d ago
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
NASDAQ · 5d ago
Sage Therapeutics Price Target Cut to $19.00/Share From $34.00 by Scotiabank
Dow Jones · 5d ago
Sage Therapeutics Is Maintained at Sector Outperform by Scotiabank
Dow Jones · 5d ago
Scotiabank Maintains Sector Outperform on Sage Therapeutics, Lowers Price Target to $19
Benzinga · 5d ago
Sage Therapeutics Is Maintained at Perform by Oppenheimer
Dow Jones · 5d ago
Sage Therapeutics Price Target Cut to $17.00/Share From $25.00 by Oppenheimer
Dow Jones · 5d ago
Oppenheimer Maintains Perform on Sage Therapeutics, Lowers Price Target to $17
Benzinga · 5d ago
In-Depth Examination Of 9 Analyst Recommendations For Sage Therapeutics
Sage Therapeutics (NASDAQ:SAGE) underwent analysis by 9 analysts in the last quarter. The company is a clinical-stage biopharmaceutical company focused on brain health medicines. The average 12-month price target of $23.67 is lower than the previous average of $24.00 for the company. The analysts' evaluations of the company show a spectrum of viewpoints from bullish to bearish.
Benzinga · 5d ago
Sage Therapeutics: Reassessing Investment Post Parkinson's Failure (Rating Upgrade)
Seeking Alpha · 5d ago
Sage Therapeutics Price Target Cut to $16.00/Share From $30.00 by TD Cowen
Dow Jones · 5d ago
Sage Therapeutics Is Maintained at Buy by TD Cowen
Dow Jones · 5d ago
TD Cowen Maintains Buy on Sage Therapeutics, Lowers Price Target to $16
Benzinga · 5d ago
More
Webull provides a variety of real-time SAGE stock news. You can receive the latest news about Sage Therapeutic through multiple platforms. This information may help you make smarter investment decisions.
About SAGE
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.